May 3rd 2024
Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CDX-1401 in Combination with Decitabine in Patients with MDS
April 1st 2014Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia
Watch
An Overview of ABT-199 for the Treatment of CLL
February 12th 2014Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.
Watch
A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
January 24th 2014Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Watch
Idelalisib: A PI3K Inhibitor on the Horizon
January 9th 2014Idelalisib is a potent and highly selective PI3K inhibitor that promotes apoptosis in primary cells from patients with different B-cell malignancies. Idelalisib has been shown to affect microenvironmental signaling and cell survival both in vitro and in vivo.
Read More
Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
January 8th 2014Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Watch
Idelalisib Improves Outcomes in Heavily-Pretreated CLL
December 14th 2013A combination of rituximab (Rituxan) and the PI3K-delta inhibitor idelalisib was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL).
Read More
Updated Data Continues to Back Ibrutinib in CLL
December 13th 2013At the 55th Annual Meeting of the American Society of Hematology (ASH), several trials of ibrutinib both alone and in combination with currently used therapies for patients with chronic lymphocytic leukemia (CLL) were presented.
Read More
Frontline Ofatumumab Efficacious in Older CLL Patients
December 11th 2013In patients with previously untreated chronic lymphocytic leukemia (CLL) who are considered inappropriate for fludarabine, the addition of ofatumumab to chlorambucil improves clinical outcomes and is tolerable irrespective of patient age or fitness.
Read More
A Preview of the 2013 ASH Annual Meeting
December 5th 2013Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Read More